{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:33:30Z","timestamp":1787063610466,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prior research has highlighted the association between uric acid (UA) and the activation of the renin-angiotensin-aldosterone system (RAAS). However, the specific relationship between aldosterone, the RAAS\u2019s end product, and UA-related diseases remains poorly understood. This study aims to clarify the impact of aldosterone on the development and progression of hyperuricemia and gout in hypertensive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study involved 34534 hypertensive participants, assessing plasma aldosterone concentration (PAC)\u2019s role in UA-related diseases, mainly hyperuricemia and gout. We applied multiple logistic regression to investigate the impact of PAC and used restricted cubic splines (RCS) for examining the dose-response relationship between PAC and these diseases. To gain deeper insights, we conducted threshold analyses, further clarifying the nature of this relationship. Finally, we undertook subgroup analyses to evaluate PAC\u2019s effects across diverse conditions and among different subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariate logistic regression analysis revealed a significant correlation between the occurrence of hyperuricemia and gout and the elevation of PAC levels. Compared to the first quartile (Q1) group, groups Q2, Q3, and Q4 all exhibited a significantly increased risk of occurrence. Moreover, the conducted RCS analysis demonstrated a significant nonlinear dose-response relationship, especially when PAC was greater than 14 ng\/dL, with a further increased risk of hyperuricemia and gout. Finally, comprehensive subgroup analyses consistently reinforced these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates a close association between elevated PAC levels and the development of UA-related diseases, namely hyperuricemia and gout, in hypertensive patients. Further prospective studies are warranted to confirm and validate this relationship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2024.1424207","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:29:56Z","timestamp":1722299396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuaiwei","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108615","article-title":"Uric acid in health and disease: From physiological functions to pathogenic mechanisms","volume":"256","author":"Wen","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.139","article-title":"Screening for hyperuricaemia and gout: a perspective and research agenda","volume":"10","author":"Stamp","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.056","article-title":"Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease","volume":"98","author":"Ponticelli","year":"2020","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2147","article-title":"Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2 diabetes: an observational analysis from the treatment options for type 2 diabetes in adolescents and youth (TODAY) study","volume":"42","author":"Bjornstad","year":"2019","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney diseases: Off J Natl Kidney Foundation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s40520-024-02746-2","article-title":"Association of serum uric acid with functional disability in older subjects: a population-based study","volume":"36","author":"Laudisio","year":"2024","journal-title":"Aging Clin Exp Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/nu14194095","article-title":"The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017","volume":"14","author":"Piao","year":"2022","journal-title":"Nutrients"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.907952","article-title":"Folic acid and zinc improve hyperuricemia by altering the gut microbiota of rats with high-purine diet-induced hyperuricemia","volume":"13","author":"Sun","year":"2022","journal-title":"Front Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1814","article-title":"Sugar, uric acid, and the etiology of diabetes and obesity","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0004-x","article-title":"An update on the genetics of hyperuricaemia and gout","volume":"14","author":"Major","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.161486","article-title":"Primary aldosteronism: a common cause of resistant hypertension","volume":"189","author":"Kline","year":"2017","journal-title":"CMAJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12356","article-title":"Hypertension and obesity: correlates with renin-angiotensin-aldosterone system and uric acid","volume":"16","author":"Ruiz-Hurtado","year":"2014","journal-title":"J Clin hypertension (Greenwich Conn)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-830","article-title":"Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation","volume":"11","author":"Wang","year":"2021","journal-title":"Cardiovasc diagnosis Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000355405","article-title":"Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome","volume":"3","author":"Chaudhary","year":"2013","journal-title":"Cardiorenal Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1042\/cs0490613","article-title":"Plasma uric acid concentration related to the urinary excretion of aldosterone and of electrolytes in normal subjects","volume":"49","author":"Ramsay","year":"1975","journal-title":"Clin Sci Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2016.12.008","article-title":"Serum uric acid is not independently associated with plasma renin activity and plasma aldosterone in hypertensive adults","volume":"27","author":"Mul\u00e8","year":"2017","journal-title":"Nutrition metabolism Cardiovasc diseases: NMCD"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S408722","article-title":"Relationship between plasma aldosterone concentrations and non-alcoholic fatty liver disease diagnosis in patients with hypertension: A retrospective cohort study","volume":"16","author":"Hu","year":"2023","journal-title":"Diabetes Metab syndrome obesity: Targets Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1038\/s41598-024-54971-4","article-title":"Association of the trajectory of plasma aldosterone concentration with the risk of cardiovascular disease in patients with hypertension: a cohort study","volume":"14","author":"Cai","year":"2024","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DDDT.S466904","article-title":"Effectiveness of spironolactone in reducing osteoporosis and future fracture risk in middle-aged and elderly hypertensive patients","volume":"18","author":"Song","year":"2024","journal-title":"Drug design Dev Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1373862","article-title":"Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk","volume":"15","author":"Song","year":"2024","journal-title":"Front endocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2021.07.002","article-title":"Positive association between body fat percentage and hyperuricemia in patients with hypertension: The China H-type hypertension registry study","volume":"31","author":"Xiong","year":"2021","journal-title":"Nutrition metabolism Cardiovasc diseases: NMCD"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.02.023","article-title":"Temporal relationship between hyperuricemia and hypertension and its impact on future risk of cardiovascular disease","volume":"111","author":"Tian","year":"2023","journal-title":"Eur J Internal Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.dsx.2020.01.007","article-title":"Management of asymptomatic hyperuricemia: Integrated Diabetes & Endocrine Academy (IDEA) consensus statement","volume":"14","author":"Valsaraj","year":"2020","journal-title":"Diabetes Metab syndrome"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann rheumatic Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1754","article-title":"Gout: diagnosis and management-summary of NICE guidance","volume":"378","author":"Neilson","year":"2022","journal-title":"BMJ (Clinical Res ed)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet (London England)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-003-0072-y","article-title":"Hyperuricemia and gout","volume":"5","author":"Liot\u00e9","year":"2003","journal-title":"Curr Rheumatol Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1161\/HYPERTENSIONAHA.117.10370","article-title":"Uric acid is a strong risk marker for developing hypertension from prehypertension: A 5-year Japanese cohort study","volume":"71","author":"Kuwabara","year":"2018","journal-title":"Hypertension (Dallas Tex: 1979)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.899563","article-title":"The role of uric acid in hypertension of adolescents, prehypertension and salt sensitivity of blood pressure","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci monitor: Int Med J Exp Clin Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension (Dallas Tex: 1979)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2213559","article-title":"Aldosterone and treatment-resistant hypertension","volume":"388","author":"Leopold","year":"2023","journal-title":"New Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/13813455.2018.1509220","article-title":"Blockade of mineralocorticoid receptor ameliorates oral contraceptive-induced insulin resistance by suppressing elevated uric acid and glycogen synthase kinase-3 instead of circulating mineralocorticoid","volume":"126","author":"Adeyanju","year":"2020","journal-title":"Arch Physiol Biochem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9966372","article-title":"Suppression of adenosine deaminase and xanthine oxidase activities by mineralocorticoid and glucocorticoid receptor blockades restores renal antioxidative barrier in oral contraceptive-treated dam","volume":"2021","author":"Badmus","year":"2021","journal-title":"J renin-angiotensin-aldosterone system: JRAAS"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.0954-6820.1983.tb03684.x","article-title":"The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives","volume":"213","author":"Falch","year":"1983","journal-title":"Acta Med Scandinavica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12504","article-title":"Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms","volume":"20","author":"Ohashi","year":"2015","journal-title":"Nephrol (Carlton Vic)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003049","article-title":"Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study","volume":"40","author":"Lin","year":"2022","journal-title":"J hypertension"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118867","article-title":"Role of aldosterone in the remnant kidney model in the rat","volume":"98","author":"Greene","year":"1996","journal-title":"J Clin Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.05.009","article-title":"Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis","volume":"65","author":"Xia","year":"2016","journal-title":"Metabolism: Clin experimental"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638732","article-title":"The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship","volume":"2014","author":"Kim","year":"2014","journal-title":"BioMed Res Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000170379.08214.5a","article-title":"Participation of aldosterone in the vascular inflammatory response of spontaneously hypertensive rats: role of the NFkappaB\/IkappaB system","volume":"23","author":"Sanz-Rosa","year":"2005","journal-title":"J hypertension"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J hypertension"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjnut.2023.05.014","article-title":"Association of the oxidative balance score and cognitive function and the mediating role of oxidative stress: evidence from the national health and nutrition examination survey (NHANES) 2011-2014","volume":"153","author":"Song","year":"2023","journal-title":"J Nutr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.2c01513","article-title":"Naringenin Ameliorates Hyperuricemia by Regulating Renal Uric Acid Excretion via the PI3K\/AKT Signaling Pathway and Renal Inflammation through the NF-\u03baB Signaling Pathway","volume":"71","author":"Yang","year":"2023","journal-title":"J Agric Food Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251333","article-title":"Association between serum uric acid and left ventricular hypertrophy\/left ventricular diastolic dysfunction in patients with chronic kidney disease","volume":"16","author":"Kim","year":"2021","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms20205214","article-title":"Endothelial dysfunction in primary aldosteronism","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.3390\/ijms22179221","article-title":"Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.05.011","article-title":"Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases","volume":"53","author":"Queisser","year":"2012","journal-title":"Free Radical Biol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20710","article-title":"Aldosterone induces oxidative stress, oxidative DNA damage and NF-\u03baB-activation in kidney tubule cells","volume":"50","author":"Queisser","year":"2011","journal-title":"Mol carcinogenesis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2174\/138161205774913255","article-title":"Uric acid and oxidative stress","volume":"11","author":"Glantzounis","year":"2005","journal-title":"Curr Pharm design"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension (Dallas Tex: 1979)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2012.07.009","article-title":"Renal transport of uric acid: evolving concepts and uncertainties","volume":"19","author":"Bobulescu","year":"2012","journal-title":"Adv chronic Kidney disease"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1424207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:30:00Z","timestamp":1722299400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1424207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":55,"alternative-id":["10.3389\/fendo.2024.1424207"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1424207","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1424207"}}